Last updated: Oct 7, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT07057596 | 2 | Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma | gp100 peptide-HLA-A*02:01 -- T cell receptor (TCR) bispecific fusion protein (Tebentafusp) |
| NCT05607095 | 1 | A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma | Tumor infiltrating lymphocytes (TILs) -- adoptive cell therapy |
| NCT07804186 | 3 | Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma | PKC (Protein Kinase C) -- kinase inhibitor (Darovasertib); ALK and MET -- kinase inhibitor (Crizotinib) |
| NCT05903937 | 1 | Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases | Tumor infiltrating lymphocytes (TIL) -- adoptive cell therapy + alkylating agent (melphalan) + IL-2 -- cytokine |
| NCT06070012 | 2 | Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma | gp100 peptide-HLA-A*0201 complex -- bispecific T cell engager (ImmTAC) |
| Sponsor | Recruiting trials |
|---|---|
| Vastra Gotaland Region | 3 |
| H. Lee Moffitt Cancer Center and Research Institute | 3 |
| University of Miami | 2 |
| Thomas Jefferson University | 2 |
| St Vincent's Hospital, Sydney | 2 |
Countries/regions with the most active trial sites for uveal melanoma. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Jan 31, 2027 | NCT05903937 | Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases | Tumor infiltrating lymphocytes (TIL) -- adoptive cell therapy + alkylating agent (melphalan) + IL-2 -- cytokine |
| Jan 2027 | NCT07183852 | Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma | Tumor-infiltrating lymphocytes + melphalan + IL-2 -- adoptive cell therapy + chemotherapy + cytokine |
| Jun 29, 2026 | NCT07501117 | Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma | CTLA-4 + PD-1 -- immune checkpoint inhibitors (monoclonal antibodies) |
| Mar 2, 2026 | NCT07627698 | Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma | CSPG4 + GD2 -- dual-target chimeric antigen receptor natural killer cells (CAR-NK) |
| Feb 1, 2026 | NCT07203391 | Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis | PI3Kdelta -- small molecule inhibitor (Roginolisib) |
| Dec 3, 2025 | NCT06961357 | Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma | CD40L + tumor antigens -- CD40L-augmented tumor infiltrating lymphocytes (cell therapy) |
| Oct 15, 2025 | NCT06626516 | Tebentafusp-tebn With LDT in Metastatic UM | gp100 peptide-HLA-A*0201 + T cell receptor -- bispecific T cell engager (ImmTAC) |
You've seen the uveal melanoma landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.